iiinova — where your digital self keeps evolving

International Society of Glomerular Disease @isgd.bsky.social · 3h

Huge thanks to our amazing faculty for their time and expertise! 🙌 Next stop: Clinical Trials Bootcamp in Mar del Plata, Argentina! 🇦🇷 Stay tuned. 3/3 #ISGD #ClinicalTrials #Nephrology #GlomerularDisease #ESPN2026 #PediatricNephrology #CTB #nephtwitter

000

International Society of Glomerular Disease @isgd.bsky.social · 3h

Our mission? Preparing young nephrologists to join the clinical trial workforce. 🤝 It was incredible to connect early-career professionals with senior faculty and industry partners to drive the future of kidney medicine. 2/3

100

International Society of Glomerular Disease @isgd.bsky.social · 3h

🎉 Last week’s ISGD Pediatric Clinical Trials Bootcamp at the IPNA-ESPN Junior Master Class in Bordeaux! With 100+ in the room and 100+ online, we are thrilled to see the global community come together. 🌍🧵 1/3

110

International Society of Glomerular Disease @isgd.bsky.social · 24/09/2026

⏰ Time is running out! Registration for the ISGD Clinical Trials Summit 2026 closes October 1. Meet the industry experts. Connect with leaders. Be part of what’s next. 📅 November 13–15, 2026 | Galveston, TX 🔗 Register now: www.is-gd.org/2026-cts #ISGD #ClinicalTrials

000

International Society of Glomerular Disease @isgd.bsky.social · 22/09/2026

Clinical trial bootcamp training @ ALANEPE Congress 2026 🇦🇷. ISGD is proud to host our Clinical Trials Bootcamp on Oct. 28 in Mar del Plata, Argentina. Looking forward to provide this training to over 120 Latam peds nephs! Learn more: www.is-gd.org/ctbalanepe #ISGD #ALANEPE2026

020

International Society of Glomerular Disease @isgd.bsky.social · 11/09/2026

Don't Wait. Submit Now. Late-Breaking Abstracts Open Through October 1.

000

International Society of Glomerular Disease @isgd.bsky.social · 10/09/2026

🚀 The future of pediatric clinical trials starts here! ISGD Pediatric Clinical Trials Bootcamp is coming to ESPN 2026. Practical training, mentorship & networking to prepare the next generation of trial investigators 👉 Register now! congressespn.org/ipna-espn-ju... #ISGD #ESPN2026 #ClinicalTrials

030

International Society of Glomerular Disease @isgd.bsky.social · 08/09/2026

ISGD meets in Philadelphia. A meaningful visit to the Hospital of the University of Pennsylvania brought together colleagues, clinical perspectives, and important conversations about the future of glomerular medicine. Connecting. Learning. Advancing. Together. @tobias-b-huber.bsky.social

000

International Society of Glomerular Disease @isgd.bsky.social · 04/09/2026

Six more experts. Six more perspectives. One big goal. 🔬 Meet more of the incredible speakers joining the ISGD Clinical Trials Summit in Galveston, Nov. 13–15! 🌎 Clinical trials. Collaboration. The future of glomerular medicine. 👉 is-gd.org/2026-CTS

000

International Society of Glomerular Disease @isgd.bsky.social · 03/09/2026

🌊 Your research belongs in Galveston! The ISGD Clinical Trials Summit 2026 is calling for Late Breaking Abstracts! 📅 Opens Sept. 1 ⏰ Deadline Oct. 1 Share your latest research with leaders in glomerular disease. 🔬 Submit: www.is-gd.org/cts-2026-lat...

000

International Society of Glomerular Disease @isgd.bsky.social · 25/08/2026

100

International Society of Glomerular Disease @isgd.bsky.social · 21/08/2026

🌎 ISGD welcomes 4 new Board leaders! 🔬 Kretzler — translational research 🧪 Rovin — clinical trials 👧 Vivarelli — pediatric nephrology 💜 Lightstone — lupus nephritis & patient advocacy 👉 Read more: www.is-gd.org/en/news-from...

is-gd.org

ISGD Welcomes 4 New Board Appointments

ISGD Welcomes Four New Board Appointments

020

International Society of Glomerular Disease @isgd.bsky.social · 18/08/2026

ISGD’s Clinical Trials BootCamp is building the next generation of trial-ready kidney investigators and sites through education, mentorship & collaboration. Featured in *ASN Kidney News*. **Why ISGD? Why Now?** Read more: www.kidneynews.org/view/journal... #ISGD #ClinicalTrials

kidneynews.org

010

International Society of Glomerular Disease @isgd.bsky.social · 06/08/2026

✨ Only 100 days until the inaugural 2026 ISGD Clinical Trials Summit! We’re spotlighting our outstanding Program Advisory Committee, whose expertise is shaping an exciting, forward-thinking program. Join us in Galveston! 🌎 🧬 Register Now: www.is-gd.org/2026-cts @tobias-b-huber.bsky.social

021

International Society of Glomerular Disease @isgd.bsky.social · 30/07/2026

🚨 The countdown is on! August 1 is your last chance to save with early registration and submit your abstract for the inaugural ISGD Clinical Trials Summit, hosted by UTMB. Join us Nov. 13–15 in Galveston, TX. 🔗 Register: www.is-gd.org/2026-cts ➤ Submit your abstract: www.is-gd.org/cts-2026-abs...

110

International Society of Glomerular Disease @isgd.bsky.social · 24/07/2026

🚨 August 1 is almost here! Register early and submit your abstract for the 2026 ISGD Clinical Trials Summit, hosted by UTMB. Join leading experts in glomerular disease Nov. 13–15 in Galveston, TX! Register today: www.is-gd.org/2026-cts Submit an Abstract: www.is-gd.org/cts-2026-abs...

110

International Society of Glomerular Disease @isgd.bsky.social · 20/07/2026

🎙️New #GNin10 Ready to level up your MN knowledge from IgG1 to IgG4? 🧬 In our latest Board Review Bonus, Dr. Kenar Jhaveri & Dr. Koyal Jain break down Membranous Nephropathy—from biopsy "spikes" to the "Koyal-Kenar" risk criteria! 🎧 share.transistor.fm/s/03967a4b ⛱️ PARASOL-MN: is-gd.org/parasol

101

International Society of Glomerular Disease @isgd.bsky.social · 05/07/2026

🍁 We wrapped up June with another ISGD Preceptorship at @uoftmedicine.bsky.social! Thanks Arenn Jauhal & Heather Reich for a fascinating 2-day program on complement-mediated GD! Learned so much & worked on solving so many problems 🍁 The GD patients of Canada are in very good hands!

040

International Society of Glomerular Disease @isgd.bsky.social · 02/07/2026

When we say the International Society of Glomerular Disease, we mean INTERNATIONAL. 🌍 In partnership with UTMB, the inaugural ISGD Clinical Trials Summit 2026 brings together speakers from 12+ countries and scholarship applicants from 5+ countries. Register now: www.is-gd.org/2026-cts #ISGD #UTMB

120

International Society of Glomerular Disease @isgd.bsky.social · 24/06/2026

📢 Abstract deadline extended! Submit your work to ISGD's Inaugural Clinical Trials Summit by August 1, 2026. Share innovations in kidney disease clinical trials, biomarkers, patient engagement, trial design and more! 🔗 www.is-gd.org/cts-2026-abs... #ISGD #KidneyResearch @tobias-b-huber.bsky.social

010

International Society of Glomerular Disease @isgd.bsky.social · 23/06/2026

💗 Congrats to @tobias-b-huber.bsky.social, honored with this year's Münster Heart Center Lecture! 🫀 A well-deserved recognition of the vital link between kidney & heart health. He also signed Münster’s historic Golden Book in the Hall of Peace, joining the likes of Obama, the Dalai Lama & QEII 📖

010

International Society of Glomerular Disease @isgd.bsky.social · 19/06/2026

High-yield takeaways: The "Big Three" hematuria differential Why TBMD sits on the Alport spectrum EM pearls: Spotting "basket-weave" splitting 🚨 AVOID immunosuppression for secondary FSGS 3-4% risk of de novo anti-GBM post-transplant

010

International Society of Glomerular Disease @isgd.bsky.social · 19/06/2026

🚨New GN in 10🎙️ Think Alport's only affects males 🧬? Think again! @kdjhaveri.bsky.social & Koyal Jain provide a comprehensive clinical overview of hereditary nephritis—aka Alport syndrome. 🎧 Listen here: share.transistor.fm/s/434d7408 #AlportSyndrome #ISGD #GNin10 @tobias-b-huber.bsky.social

100

International Society of Glomerular Disease @isgd.bsky.social · 13/06/2026

🔬 Join leading experts at ISGD’s first Clinical Trials Summit this November! Explore the latest in GD regulatory advances, patient engagement, biomarkers, and recruitment strategies! 🗓️ Nov 13–15, 2026 📍 Galveston, TX 🔗 www.is-gd.org/2026-cts #ISGD #ClinicalTrials @tobias-b-huber.bsky.social

000

International Society of Glomerular Disease @isgd.bsky.social · 08/06/2026

#ERA26 🏴󠁧󠁢󠁳󠁣󠁴󠁿✨ Challenging our thinking in nephrology and in glomerular diseases. Proud to see many members taking center stage. The ISGD team was grateful to spend time with so many of our members and partners committing to better outcomes and lives for our patients. #GlomerularDisease #KidneyHealth

020

International Society of Glomerular Disease @isgd.bsky.social · 01/06/2026

Starting the week with an ISGD Preceptorship at the UK’s National Renal Complement Therapeutics Centre 🤩 @newcastleuni.bsky.social

000

International Society of Glomerular Disease @isgd.bsky.social · 26/05/2026

🚨 Late-Breaking Abstract Submissions are open for the 2026 ISGD Clinical Trials Summit! Share your findings with the global glomerular disease research community. 🗓️ Nov 13–15, 2026 📍 Galveston, TX Submit: www.is-gd.org/cts-2026-abs...  Register: www.is-gd.org/2026-cts @tobias-b-huber.bsky.social

000

International Society of Glomerular Disease @isgd.bsky.social · 18/05/2026

The updated ISGD Clinical Trials Summit Agenda Highlights are here! FDA panels, patient voices, late-breaking research, trial innovation, and more! @tobias-b-huber.bsky.social 🗓️ Nov 13–15, 2026 📍Galveston, TX Register: www.is-gd.org/2026-cts #ISGD #ClinicalTrials #Nephrology #KidneyResearch

000

International Society of Glomerular Disease @isgd.bsky.social · 01/05/2026

EM Pearls: Can you differentiate amyloid fibrils from mimics like fibrillary GN or immunotactoid GN based on diameter? 📏 Plus, insights on RAAS inhibition and transplant outcomes. Check out the full concept map and resources here: www.nephronpower.com/2021/06/conc...

000

International Society of Glomerular Disease @isgd.bsky.social · 01/05/2026

The tissue is the issue! 🔬 The hosts discuss why biopsying the affected organ is non-negotiable and how mass spectrometry directs therapy. They also explore rare variants like LECT2 and hereditary types (ATTR, fibrinogen A alpha-chain). 🧬 @tobias-b-huber.bsky.social

100

International Society of Glomerular Disease @isgd.bsky.social · 01/05/2026

New GN in 10 Board Review Bonus! 🎧 Hosts @kdjhaveri.bsky.social & Dr. Koyal Jain tackle the complexities of Kidney Amyloidosis. From "mushy" microscopy to the precision of mass spectrometry, this episode is a must-listen for the global #NephTwitter community. Listen here: bit.ly/4cIvNkP

132

International Society of Glomerular Disease @isgd.bsky.social · 28/04/2026

The time is finally here: A sneak peek of the Agenda Highlights for ISGD’s 2026 Clinical Trial Summit with UTMB, bringing together leaders advancing glomerular disease research. Join us Nov. 13–15, 2026 in Galveston, TX. Register: www.is-gd.org/2026-cts Questions/sponsorship: ctsummit@is-gd.org

111

Reposted by International Society of Glomerular Disease

NephMadness @nephmadness.bsky.social · 28/04/2026

Thank you to these podcasts on #NephMadness 2026: - GN in Ten @isgd.bsky.social - Global Kidney Care @theisn.org - @freelyfiltered.bsky.social - @febrilepodcast.com - @nkf-professionals.bsky.social - @coreimpodcast.bsky.social - Nephron Segment bit.ly/NM26podcrawl

142

International Society of Glomerular Disease @isgd.bsky.social · 14/04/2026

Thank you to our PARASOL partners @nkf-professionals.bsky.social @asnkidney.bsky.social and Nephcure, PARASOL PIs Laura Mariani and Matthias Kretzler, lead biostatistician Abigail Smith, Margaret Helmuth and the data analysis core at @miktmc.bsky.social, and EVERYONE involved in the project!

010

International Society of Glomerular Disease @isgd.bsky.social · 14/04/2026

More than 100 years after #FSGS was first described, we have the first FDA-approved treatment. A proud day for the collaborative #ParasolProject! With the global community uniting to transform glomerular health, this is only the beginning. ⛱️

is-gd.org

A Milestone for FSGS — And a Proud Moment for PARASOL

A historic milestone for FSGS patients as the FDA approves the first drug for the condition, highlighting the collaborative efforts behind the PARASOL project's success.

151

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

Take-home from WCN26: IgAN treatment is shifting from nonspecific immunosuppression to pathway-directed therapy. The debate is no longer whether to treat, but where in the pathway to intervene first. 🧵 (10) #GlomerularDisease #ISNWCN

010

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

Future IgAN management may involve combination or sequential therapy: • Gut-targeted immunomodulation • Complement inhibition • Possibly BAFF/APRIL blockade Precision treatment for a heterogeneous disease. 🧵 (9) #GlomerularDisease #ISNWCN

110

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

🔑 clinical question: Should therapy first target the cause of IgAN or the mechanism of kidney injury? This remains unresolved and likely depends on patient phenotype. 🧵(8) #GlomerularDisease #ISNWCN

110

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

However, mechanisms differ. Nefecon → modifies disease origin (gut immune system) Complement inhibitors → block final inflammatory pathway in kidney Upstream control vs downstream protection. 🧵 (7) #GlomerularDisease #ISNWCN

110

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

In APPLAUSE-IgAN: Iptacopan reduced the risk of the composite kidney failure endpoint by 43% vs placebo (HR ≈0.57). Strong signal for complement blockade in IgAN progression. 🧵 (6) #GlomerularDisease #ISNWCN

110

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

Clinical trials show both strategies slow disease progression. NefIgArd (Nefecon): ✔ Reduced proteinuria ✔ Slower eGFR decline APPLAUSE-IgAN (iptacopan): ✔ Reduced proteinuria ✔ Lower risk of kidney failure events 🧵 (5) #GlomerularDisease #ISNWCN

110

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

Complement inhibitors such as Iptacopan: • Block the alternative complement pathway • Reduce inflammatory injury in the glomerulus They act downstream, after immune complexes reach the kidney. 🧵 (4) #GlomerularDisease #ISNWCN

110

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

Targeted-release budesonide (Nefecon): • Acts in the terminal ileum • Suppresses mucosal immune activation • Reduces production of pathogenic Gd-IgA1 In short: it targets the upstream driver of disease. 🧵 (3) #GlomerularDisease #ISNWCN

110

International Society of Glomerular Disease @isgd.bsky.social · 30/03/2026

IgAN pathogenesis follows a multi-hit model: 1️⃣ Mucosal immune dysregulation → galactose-deficient IgA1 2️⃣ Autoantibody formation 3️⃣ Immune complex formation 4️⃣ Glomerular deposition + complement activation Therapies target different steps. 🧵 (2) #GlomerularDisease #ISNWCN

110